Metastatic Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas: A surgeon's plea to centering attention on the liver
Over 50% of patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) have stage IV disease at presentation and the most likely organ to be affected by metastases is the liver. Hepatic involvement and hepatic tumor burden is a key prognostic factor affecting survival of these patients and 80% eventually die of liver failure due to tumor dissemination within the liver. This commentary explores the efficacy and limitations of systemic treatments in patients with GEP-NETs and liver metastases.
Source: Seminars in Oncology - Category: Cancer & Oncology Authors: Xavier M Keutgen, Erik Schadde, Rodney F Pommier, Thorvardur R Halfdanarson, James Howe, Electron Kebebew Source Type: research
More News: Brain | Cancer & Oncology | Gastroenterology | Liver | Neurology | Neurosurgery | Pancreas | Urology & Nephrology